Intra-Cellular Therapies (ITCI) Tops Q3 EPS by 24c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. ORCL
2. SPY
3. GMAB
4. ACCV
5. FLG
6. META
7. FICO
8. SMMT
9. QQQ
10. SPCX

Go back to Intra-Cellular Therapies (ITCI) Tops Q3 EPS by 24c

Intra-Cellular Therapies Reports Third Quarter 2022 Financial Results and Provides Corporate Update

November 3, 2022 7:30 AM EDT

CAPLYTA net product revenues for the third quarter 2022 were $71.9 million, compared to $21.6 million for the same period in 2021, representing a 233% increase over the same period in 2021 and a 30% increase over the second quarter 2022

Third quarter 2022 CAPLYTA total prescriptions increased 220%, versus the same period in 2021 and 26% sequentially versus the second quarter 2022

NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the third quarter ended September 30, 2022 and... More